Anti-CfaE nanobodies provide broad cross-protection against major pathogenic enterotoxigenic Escherichia coli strains, with implications for vaccine design by Amcheslavsky, Alla et al.
University of Massachusetts Medical School 
eScholarship@UMMS 
Open Access Publications by UMMS Authors 
2021-02-02 
Anti-CfaE nanobodies provide broad cross-protection against 
major pathogenic enterotoxigenic Escherichia coli strains, with 
implications for vaccine design 
Alla Amcheslavsky 
University of Massachusetts Medical School 
Et al. 
Let us know how access to this document benefits you. 
Follow this and additional works at: https://escholarship.umassmed.edu/oapubs 
 Part of the Bacterial Infections and Mycoses Commons, Bacteriology Commons, Immunopathology 
Commons, Immunoprophylaxis and Therapy Commons, Immunotherapy Commons, Infectious Disease 
Commons, and the Pathogenic Microbiology Commons 
Repository Citation 
Amcheslavsky A, Wallace AL, Monir E, Li Q, Stoppato M, Giuntini S, Schiller ZA, Pondish JR, Toomey JR, 
Schneider RM, Meisinger J, Klempner MS, Cavacini LA, Wang Y. (2021). Anti-CfaE nanobodies provide 
broad cross-protection against major pathogenic enterotoxigenic Escherichia coli strains, with 
implications for vaccine design. Open Access Publications by UMMS Authors. https://doi.org/10.1038/
s41598-021-81895-0. Retrieved from https://escholarship.umassmed.edu/oapubs/4620 
Creative Commons License 
This work is licensed under a Creative Commons Attribution 4.0 License. 
This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in Open Access 
Publications by UMMS Authors by an authorized administrator of eScholarship@UMMS. For more information, 
please contact Lisa.Palmer@umassmed.edu. 
1
Vol.:(0123456789)
Scientific Reports |         (2021) 11:2751  | https://doi.org/10.1038/s41598-021-81895-0
www.nature.com/scientificreports
Anti‑CfaE nanobodies provide 
broad cross‑protection 
against major pathogenic 
enterotoxigenic Escherichia 
coli strains, with implications 
for vaccine design
Alla Amcheslavsky1, Aaron L. Wallace1, Monir Ejemel1, Qi Li1, Conor T. McMahon2, 
Matteo Stoppato1, Serena Giuntini1, Zachary A. Schiller1, Jessica R. Pondish1, 
Jacqueline R. Toomey1, Ryan M. Schneider1, Jordan Meisinger1, Raimond Heukers3, 
Andrew C. Kruse2, Eileen M. Barry4, Brian G. Pierce5, Mark S. Klempner1, Lisa A. Cavacini1 & 
Yang Wang1*
Enterotoxigenic Escherichia coli (ETEC) is estimated to cause approximately 380,000 deaths annually 
during sporadic or epidemic outbreaks worldwide. Development of vaccines against ETEC is very 
challenging due to the vast heterogeneity of the ETEC strains. An effective vaccines would have to 
be multicomponent to provide coverage of over ten ETEC strains with genetic variabilities. There is 
currently no vaccine licensed to prevent ETEC. Nanobodies are successful new biologics in treating 
mucosal infectious disease as they recognize conserved epitopes on hypervariable pathogens. 
Cocktails consisting of multiple nanobodies could provide even broader epitope coverage at a lower 
cost compared to monoclonal antibodies. Identification of conserved epitopes by nanobodies can 
also assist reverse engineering of an effective vaccine against ETEC. By screening nanobodies from 
immunized llamas and a naïve yeast display library against adhesins of colonization factors, we 
identified single nanobodies that show cross‑protective potency against eleven major pathogenic 
ETEC strains in vitro. Oral administration of nanobodies led to a significant reduction of bacterial 
colonization in animals. Moreover, nanobody‑IgA fusion showed extended inhibitory activity in mouse 
colonization compared to commercial hyperimmune bovine colostrum product used for prevention of 
ETEC‑induced diarrhea. Structural analysis revealed that nanobodies recognized a highly‑conserved 
epitope within the putative receptor binding region of ETEC adhesins. Our findings support further 
rational design of a pan‑ETEC vaccine to elicit robust immune responses targeting this conserved 
epitope.
Enterotoxigenic Escherichia coli (ETEC) is one of the most common causes of diarrheal illness in children under 
five years of age, adults in the developing world and in travelers to endemic areas. Based on WHO reports, ETEC-
related diarrhea is one of the leading cause of death in the children under five years old in developing countries. 
Even if a child survives ETEC infection, there are long lasting effects throughout life including malnutrition, 
impaired cognitive development, learning disabilities and increased risk of non-communicable diseases in the 
 adulthood1–5. ETEC infections are characterized by diarrhea, vomiting, stomach cramps, and in some cases mild 
fever. An estimated 10 million cases per year occur among travelers and military personnel deployed in endemic 
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 regions3. When adult travelers develop ETEC diarrhea, a short course of antibiotics can reduce the duration and 
volume of diarrhea. However, ETEC strains are becoming increasingly resistant to  antibiotics4.
ETEC is a non-invasive pathogen that mediates small intestine adherence through bacterial surface structures 
that are known as colonization factors (CFs). Once bound to the small intestine, the bacteria produce toxins caus-
ing a net flow of water from enterocytes, leading to watery diarrhea. Development of an effective vaccine against 
ETEC bacterial attachment and colonization has long been considered as a promising approach against ETEC 
diarrhea. CFA/I is one of the most prevalent CFs and is composed of CfaE, the tip minor adhesin subunit, and a 
homopolymeric structural subunit, CfaB. In human clinical trials, oral administration of anti-CfaE bovine IgG 
provided protection against virulent ETEC challenge in over 60% of the test group, suggesting that an adhesin-
based vaccine could be effective to elicit endogenous production of protective  antibodies6. Recent studies in our 
laboratories demonstrated that when administered orally to mice and non-human primates, anti-CfaE human 
monoclonal antibodies inhibited bacterial colonization in the small intestine and protected animals from diar-
rhea associated with ETEC  infection7,8.
ETEC strains are antigenically diverse with over 25 types of CF and coli surface (CS) antigens having been 
 identified4,9–11. CFA/I represent the archetype of class 5 fimbriae, the largest class of human specific CFs that 
causes a majority of moderate to severe ETEC diarrheal  cases10–12. Class 5 fimbriae includes three sub-classes, 
5a (CFA/I, CS4, CS14), 5b (CS1, CS17, CS19, PCF071), and 5c (CS2). Other non-class 5 fimbriae have also been 
implicated in endemic and traveler diarrheal diseases including helical CS5, fibrillary CS3, CS21 and non-fimbrial 
CS6  adhesins13. As such, the development of a broadly protective and likely multicomponent vaccine against all 
major pathogenic ETEC strains remains one of the most important challenges in vaccine  design14,15. In theory, a 
cross-protective vaccine could be generated with a combination of intact  CFs16. However, such strategies could 
lead to unexpected instability or safety concerns, and high costs for manufacturing production. Despite advances 
in anti-ETEC vaccine research, there remains no licensed vaccine against ETEC.
The discovery of camelid heavy-chain variable domains (VHHs or nanobodies) has produced a new applica-
tion for antibody-derived  biologics17. Nanobodies consist of a highly stable and soluble single antigen-binding 
variable region (15 kDa), since they are derived from heavy chain only antibodies with no associated light 
 chains18. Unlike conventional antibodies, nanobodies can access distinct antigenic sites (e.g., enzyme active sites, 
recessed regions of viral glycoproteins) due to smaller paratope diameters and a longer complementarity-deter-
mining region 3 (CDR3) that is able to form finger-like  extensions17,19. Based on their unique characteristics, nan-
obodies can recognize conserved epitopes on hypervariable pathogens, such as HIV, poliovirus, norovirus, and 
 coronavirus20–24. Consequently, nanobodies are being studied in clinical trials for the treatment of a wide range 
of diseases by both systemic and oral administration due to their excellent solubility and  thermostability25–27.
In this study, we identified a panel of nanobodies that showed broad protective activities against eleven major 
types of disease-causing strains of ETEC. Oral administration of the selected nanobodies protected mice from 
colonization by 5 different strains of ETEC tested in vivo. Structural analysis revealed highly conserved epitopes 
shared by the nanobodies within the putative receptor binding region of ETEC adhesins. Due to the broad strain 
coverage of nanobodies discovered in this study, they could be used as prophylactic/therapeutic agents against 
diarrhea caused by multiple ETEC strains. In addition, the conserved epitope described in this study could be 
used for structure-based design of a pan-ETEC vaccine.
Results
Identification of anti‑ETEC nanobodies from immunized llama and yeast display library. To 
generate nanobodies with broad cross-reactivity against ETEC adhesins, two male llamas were subcutaneously 
immunized with N-terminal fragments of eight class 5 ETEC adhesins (Fig. 1A). Serum response to adhesins 
was measured by ELISA and PBMC were isolated to generate phage-displayed libraries of size around  108 as pre-
viously  described28. Libraries were initially used for panning on immobilized colonization factor antigens CS1 
and CS2, because of their relatively low sequence homology. Output from those pannings were used for a sub-
sequent panning round on CfaE. Periplasmic extracts were prepared and tested for binding to all eight adhesin 
antigens in ELISA. Cross-reactive clones were sent for sequence determination and further characterization. 
From these selections, 26 candidate nanobodies were selected.
In parallel, we used a recently developed library of synthetic nanobodies displayed on the surface of Sac-
charomyces cerevisiae29. Two rounds of magnetic activated cell sorting (MACS) were performed using FITC and 
AlexaFluor647-labeled N-terminal fragments of CfaE to identify CfaE binding clones (Fig. 1B). High-affinity 
binders were enriched by fluorescent activated cell sorting (FACS) with decreasing concentration of FITC labeled 
CfaE as previously  described29,30. Approximately 300 yeast clones were recovered from the yeast library screen. 
Binding of selected clones to antigen was verified by yeast surface staining against AlexaFluor647 labeled CfaE 
using flow cytometry. The clones showed a range of binding activities to CfaE (Supplemental Figure 1). All bind-
ers were subjected to additional rounds of screening for cross-reactivity against two other class 5 adhesins, CS1 
and CS2 (Fig. 1C). A total of 30 nanobodies with cross-reactivity and unique sequences were selected for further 
characterization. In addition, a competitive FACS screen was performed against a potent anti-CfaE full length 
antibody, 68-61, to identify nanobodies specific to the receptor binding region of  CfaE8. One clone, 2R215, was 
found to recognize an overlapping epitope with 68-61 (Fig. 1D, Supplemental Figure 2).
Selected anti‑CfaE nanobodies show cross‑reactivity against all class 5 colonization fac-
tors. To test the breadth of cross-reactivity, selected llama- and yeast-derived nanobodies were sequenced, 
cloned in pET-26b vector, expressed in E.coli, and examined by ELISA for binding to eight class 5 adhesins. Two 
yeast-derived clones (2R215 and 2R23) and two llama-derived clones (1D7 and 1H4) were selected based on 
their broad reactivity against multiple adhesins (Fig. 2A–D). The four lead nanobodies were then tested for inhi-
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bition of mannose resistant hemagglutination (MRHA) against an ETEC strain expressing CFA/I (H10407), the 
most prevalent class 5 adhesin. All nanobodies showed maximal inhibitory concentration  (IC100) in the micro-
molar concentration range (2.4–8 µM) (Fig. 2E). We next examined if these nanobodies had activity against 
ETEC strains expressing six other class 5 adhesins in MRHA assay. Consistent with ELISA binding data, the four 
nanobodies were cross-protective against all six strains with an  IC100 activity ranging from 0.4125 to 13.3 µM 
(Supplemental Table 1). We next examined the MRHA activity of nanobodies against ETEC strains expressing 
other pathogenic fimbrial and non-fimbrial adhesins including helical CS5, fibrillary CS3, and non-fimbrial CS6 
adhesins, as well as another common diarrhea causing adhesin CS21. Surprisingly, four nanobodies showed 
broad protection against all tested strains with an  IC100 ranging from 0.52 to 10 µM (Supplemental Table 1).
Figure 1.  Identification of anti-ETEC nanobodies from immunized llama and yeast display library. (A) 
Flowchart of llama immunization and panning. Two male llamas were subcutaneously immunized with 
N-terminal fragments of eight class 5 ETEC adhesins followed by PBMC isolation and generation of phage-
displayed libraries of  108 in size. Libraries were panned on immobilized colonization factor antigens CS1 and 
CS2. Output from those pannings was used for a subsequent panning round on CfaE. Cross-reactive clones were 
sent for sequence determination and further characterization. (B) Flowchart of selection process of synthetic 
nanobodies. Binders to CfaE from the naïve yeast-displayed library were enriched over two rounds of selection 
by performing magnetic-activated cell sorting (MACS) on yeast that were stained with purified and labeled 
CfaE. High affinity binders were selected during fluorescence-activated cell sorting (FACS) and single cell clones 
were screened for binding with CS1 and CS2. Cross-reactive clones were sent for sequence determination and 
further characterization. (C) Flow analysis demonstrating example of binding of yeast displaying nanobody 
2R23 to CfaE, CS1 and CS2 proteins. (D) Flow analysis demonstrating functional human monoclonal antibody 
68-61 competing for binding to CfaE with yeast library derived nanobody 2R215 on yeast.
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Anti‑CfaE VHH prevent ETEC colonization in the small intestine of a mouse model. The lead 
nanobodies were further evaluated in a mouse model of ETEC colonization as described  previously8 (Fig. 3A). 
Groups of five DBA/2 mice were given a mixture of bacteria and anti-CfaE nanobodies by oral gavage. All 
nanobodies were tested at 100 mg/kg, except for 2R23, which was tested at 50 mg/kg due to the low production 
yield. Twenty-four hours after challenge, the mice were euthanized and colony forming units (CFUs) in the small 
intestine were counted to determine the level of bacterial colonization. The efficacy of the anti-CfaE nanobodies 
was assessed by determining whether nanobodies could prevent adhesion/colonization of bacteria to the small 
intestine compared to an irrelevant nanobody control. In the anti-CfaE nanobody treatment groups, there was 
a log reduction of CFUs by 2.9 for 2R215, 2.3 for 1H4, 1.7 for 1D7 and 1.5 for 2R23 compared to the irrelevant 
nanobody control group (P < 0.01 for 2R215 and P < 0.05 for 2R23, 1D7 and 1H4). These results indicate that 
all four nanobodies showed significant activity in preventing colonization by H10407 strain at a dose of 50 or 
100 mg/kg (Fig. 3B).
The lead nanobody, 2R215, was then tested against pathogenic ETEC strains expressing other adhesins that 
are commonly isolated from patients with ETEC-associated diarrheal diseases, including CS1, CS3, CS5, CS6, 
and  CS2111,13. 2R215 demonstrated broad protection against all tested strains. Compared to the irrelevant control, 
Figure 2.  Selected anti-CfaE nanobodies show cross-reactivity against class 5 colonization factors. (A–D) 
Two yeast-derived clones (2R215 and 2R23) and two llama-derived clones (1D7 and 1H4) were examined by 
ELISA for binding to eight class 5 adhesins. These clones showed broad reactivity against multiple adhesins. 
Three biological replicates were performed. (E) The four lead nanobodies were tested for inhibition of mannose 
resistant hemagglutination (MRHA) against an ETEC strain expressing CFA/I (H10407). All nanobodies 
showed maximal inhibitory concentration  (IC100) in the micromolar concentration range (2.4–8 µM). Four to 
eight biological replicates were performed.
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treatment with 2R215 at 100 mg/kg resulted in significant reduction of CFUs against ETEC strains expressing 
CS1 (2.1 log, P < 0.01), CS3 (4.4 log, P < 0.001), CS5 (2.2 log, P < 0.01) and CS6 (2 log, P < 0.01), but not the strain 
expressing CS21 (1.2 log, P > 0.05) (Fig. 3C).
Multimerization enhances the potency of 2R215 in vitro and in vivo. Multimerization of single 
domain nanobodies can increase their stability and  potency28,31. To improve the potency of identified cross 
protective nanobodies, 2R215 was engineered as a dimer or trimer molecules using 3 × or 6 × (G4S) linkers in 
tandem N to C terminus orientation (Fig. 4A). Multimerized nanobodies were expressed in bacteria and puri-
fied using fused His tags (Fig. 4B). Both dimeric and trimeric 2R215 showed increased potency in Caco2 cell 
adhesion assays relative to the respective monomer. The  IC50 values were 10.213 µM for monomeric 2R215, 
5.09 µM for dimeric 2R215 and 1.06 µM for trimeric form of 2R215. (Fig. 4C). Activity in the MRHA assay was 
also improved with an  IC100 of 6.7 µM for monomeric, 1.25 for dimeric and 2.5 for the trimeric form of 2R215 
(P < 0.01 and P < 0.05 for dimeric and trimeric forms respectively) (Fig. 4D).
The dimeric and trimeric forms of 2R215 were further characterized in a mouse colonization model. Mice 
inoculated with ETEC mixed with 10 mg/kg of dimeric or trimeric forms 2R215 showed a log reduction of 3.5 
and 2.8 in colonization (P < 0.0001) compared to the monomeric 2R215 treated group at the same dose (Fig. 4E). 
Moreover, the dimeric and trimeric forms of 2R215 retained their activity when administered 2 h prior to bacteria 
challenge as compared to the monomeric form. Pre-treatment with dimeric and trimeric 2R25 reduced total 
CFUs by 1.9 log (P < 0.001) and 2 log (P < 0.01) respectively (Fig. 4F). These results indicated that multimerization 
of monomeric nanobodies result in improved intragastric stability and protective potency. It should be noted that 
our current multimerization strategy (using G4S linkers) was selected for proof of concept based upon previous 
 studies28. We anticipate that multimerization with other linkers may provide greater stability or better potency, 
which we will investigate in future studies.
Figure 3.  Anti-CfaE VHH prevent ETEC colonization in the small intestine of a mouse model. (A) Cartoon 
representation of mouse colonization experiment. VHH are pre-incubated with  107 colony forming units (CFU) 
of ETEC 1 h prior to intragastric challenge. Animals are euthanized 24 h after challenge, and bacterial colonies 
in the small intestine are counted. (B) DBA/2 mice were challenged intragastrically with  107 CFU of H10407 
pre-incubated with 100 mg/kg of VHH. For 2R23 50 mg/kg of VHH was used due to lower production yields. 
At least 5 animals were tested for each condition. Results for all VHH were significantly different from those 
for the irrelevant VHH (P < 0.01 for 2R215 and P < 0.05 for 2R23, 1D7 and 1H4). Two biological replicates were 
performed. (C) DBA/2 mice were challenged intragastrically with  107 CFU of strains expressing adhesins CS1, 
CS3, CS5, CS6, and CS21 pre-incubated with 100 mg/ml of 2R215. Treatment with 2R215 resulted in significant 
reduction of CFUs against ETEC strains expressing CS1 (2.1 log, P < 0.01), CS3 (4.4 log, P < 0.001), CS5 (2.2 log, 
P < 0.01) and CS6 (2 log, P < 0.01), but not the strain expressing CS21 (1.2 log, P > 0.05). Two biological replicates 
were performed for strain expressing CS1 adhesin. One biological replicate was performed for all other strains.
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Figure 4.  Multimerization enhances the potency of 2R215 in vitro and in vivo. (A) Cartoon representation of 
multimerization strategy. VHH 2R215 was engineered as a dimer or trimer molecules using 3 × or 6 × (G4S) 
linkers in tandem N to C terminus orientation. (B) Multimerized nanobodies were expressed in bacteria and 
purified using fused His tags. Purified multimer sizes were verified by polyacrylamide gel electrophoresis. 
(C) Dimeric and trimeric 2R215 show increased potency in Caco2 cell adhesion assays. The  IC50 values 
are 10.213 µM for monomeric 2R215, 5.09 µM for dimeric 2R215 and 1.06 µM for trimeric form of 2R215. 
Three biological replicates were performed (P < 0.05 and P < 0.01 for dimeric and trimeric forms compared to 
monomeric forms respectively. P > 0.05 when dimeric was compared to trimeric format). (D) Activity in the 
MRHA assay is improved with an  IC100 of 6.7 µM for monomeric, 1.25 for dimeric and 2.5 for the trimeric 
form of 2R215. Three biological replicates were performed. (P < 0.01 and P < 0.05 for dimeric and trimeric 
forms compared to monomeric forms respectively. P > 0.05 when dimeric was compared to trimeric format). 
(E) Mice inoculated with ETEC pre-incubated with 10 mg/kg of dimeric or trimeric forms of 2R215 showed 
a log reduction of 3.5 and 2.8 in colonization (P < 0.0001) compared to the monomeric 2R215 treated group 
at the same dose. Two biological replicates were performed. (F) The dimeric and trimeric forms of 2R215 
retained their activity when administered 2 h prior to bacteria challenge as compared to the monomeric form. 
Pre-treatment with dimeric and trimeric 2R25 reduced total CFUs by 1.9 log (P < 0.001) and 2 log (P < 0.01) 
respectively. Two biological replicates were performed.
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IgA Fc fusion enhances in vivo potency of 2R215 and 1D7. To gain effector function and improve 
mucosal stability, nanobodies could be engineered with the IgA Fc domain as IgA Fc fusionbodies (VHH-IgA) 
for oral  administration32. To engineer VHH-IgA Fc fusionbodies, 2R215 and 1D7 were grafted on to the Fc 
domain of IgA1 and IgA2 (VHH-IgA1 and VHH-IgA2) at the hinge regions as bivalent VHH-Fc  fusionbodies33 
(Fig. 5A). 2R215 and 1D7 VHH-IgA1 and VHH-IgA2 fusionbodies were expressed in Expi293 cells and the 
purified fusion protein sizes were verified by polyacrylamide gel electrophoresis (Fig. 5B). The binding of fusion-
bodies with adhesin was maintained with increased binding activities as compared to monomeric nanobody 
2R215 and 1D7 in ELISA (Fig. 5C,D). 2R215 and 1D7 fusionbodies were then tested in mouse colonization assay 
administered with ETEC strain H10407. While monomeric 2R15 and 1D7 inhibited colonization at 100 mg/kg 
(Fig. 3B), the IgA fusionbodies showed stronger inhibitory activity at a much lower dose of 10 mg/kg (Fig. 6A–
Figure 5.  IgA Fc fusion enhances in vitro potency of 2R215 and 1D7. (A) Cartoon representation of IgA 
fusion strategy. To engineer VHH-IgA Fc fusionbodies, 2R215 and 1D7 were grafted on to the Fc domain 
of IgA1 and IgA2 (VHH-IgA1 and VHH-IgA2) at the hinge regions. (B) 2R215 and 1D7 VHH-IgA1 and 
VHH-IgA2 fusionbodies were expressed in Expi293 cells and the purified fusion protein sizes were verified by 
polyacrylamide gel electrophoresis. (C,D) ELISA showing the binding of fusionbodies 2R215 and 1D7 with 
CfaE. The binding activities of fusionbodies were enhanced as compared to monomeric nanobodies. Three 
biological replicates were performed.
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Figure 6.  IgA Fc fusion enhances in vivo potency of 2R215 and 1D7. (A) Cartoon representation of pre-
treatment protocol of VHH administration. VHH are administered one or two hours prior to administration of 
 107 CFU of H10407. Animals are euthanized 24 h after challenge, and bacterial colonies in the small intestine 
are counted. (B,C) DBA/2 mice were challenged intragastrically with  107 CFU of H10407 pre-incubated with 
10 mg/kg of fusionbody. Treatment with 1D7 VHH-IgA1 resulted in 3.5 log reduction in CFU, P < 0.001) and 
2R215 VHH-IgA2 in 5 log reduction in CFU (P < 0.001). (D) Fusionbodies 2R215 and 1D7 were intragastrically 
administered one hour prior to administration of  107 CFU of H10407. Fusionbody pre-treatment resulted in 
reduction of CFUs by 1.2 log for 2R215 VHH-IgA2 (P < 0.01) and 2.7 log for 1D7 VHH-IgA1 (P < 0.0001). Two 
biological replicates were performed. (E,F) Fusionbodies 2R215 and 1D7 and Travelan were intragastrically 
administered two hours prior to administration of  107 CFU of H10407. A 1.7 log reduction in total CFUs 
was observed in 1D7 VHH-IgA1 treated animals as compared to the group treated with irrelevant control 
(P < 0.0001). Two biological replicates were performed.
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D). Next, the most potent fusionbodies, 1D7 VHH-IgA1 (3.5 log reduction in CFU, P < 0.001) and 2R215 VHH-
IgA2 (5 log reduction in CFU, P < 0.001), were examined in a pre-treatment model. Animals were orally inocu-
lated with fusionbodies 1 h prior to ETEC challenge. Fusionbody treatment resulted in reduction of CFUs by 
1.2 log for 2R215 VHH-IgA2 (P < 0.01) and 2.7 log for 1D7 VHH-IgA1 (P < 0.0001) (Fig. 6C,D). Furthermore, 
the 1D7 VHH-IgA1 fusionbody retained activity when the pre-treatment time was extended to 2 h. A 1.7 log 
reduction in total CFUs was observed in 1D7 VHH-IgA1 treated animals as compared to the group treated 
with irrelevant control (P < 0.0001) (Fig. 6E). We also compared the activity of the 1D7 VHH-IgA1 fusionbody 
to Travelan, a commercial hyperimmune bovine colostrum (HBS) product used for the prevention of ETEC-
induced diarrhea. While Travelan showed activity in 1 h pre-treatment when used at 40 mg/kg (Supplemental 
Figure 3), it did not inhibit colonization after 2 h of pre-treatment (Fig. 6E).
Epitope mapping of lead anti‑ETEC VHHs. To elucidate the molecular basis of the interaction between 
anti-ETEC nanobodies and adhesins, we performed computational analysis and experimental mutagenesis to 
map nanobody binding determinants. Residues of interest on CfaE were identified through analysis of side 
chain surface exposure, sequence conservation, and docking simulations (BioLuminate, Schrödinger Release 
2018-3, Schrödinger, LLC, New York, NY, 2016), and were mutated to alanine for experimental testing of effects 
on nanobody binding using ELISA. Most of the residues selected for mutagenesis are located in the putative 
receptor binding pocket, while other conserved and surface-exposed sites outside of that region were also tested.
Experimental binding affinity measurements revealed that several highly conserved residues in the putative 
receptor binding pocket are key determinants of nanobody binding (Supplemental Table 2). Binding effects of 
residue substitutions are shown on the CfaE structure for the lead nanobodies 2R215 and 1D7 in Fig. 7. Highly 
conserved receptor binding pocket residues R67 and R181 are shared determinants of 2R215 and 1D7 binding, 
in addition to residues R182 and Y183, the latter of which is well-exposed on the CfaE surface (Fig. 7B,E). Of 
note, R181 of CfaE was previously found to be critical for ETEC binding in a human in vitro organ  culture34. The 
R181A substitution had a limited effect on nanobody 1D7 binding (< 20% disruption), suggesting less engage-
ment of that residue relative to others in that region such as R67, R182 and Y183. Other residues, including L64 
and Y65, showed varying 2R215 and 1D7 binding effects for alanine substitutions, indicating fine differences 
in nanobody-adhesin recognition. Alanine substitutions of conserved residues outside of the putative receptor 
binding region were also tested, with P46A leading to no effects on binding, while Y156A unexpectedly led to 
moderate loss of nanobody binding. Given its distance from the likely nanobody binding sites, the Y156A substi-
tution likely has an allosteric effect on CfaE, leading to an alteration in the structure or dynamics in the putative 
receptor binding pocket. To view possible modes of CfaE engagement for the 2R215 and 1D7 nanobodies, we 
performed docking global simulations of the modeled nanobodies using  ZDOCK35 and the unbound structure 
of CfaE (PDB code 2HB0). Based on clustering analysis, we identified models that agree with epitope mapping 
data, with 2R215 and 1D7 models targeting key binding residues on CfaE (Fig. 7C,F).
Sequence alignment revealed that most of these residues are highly conserved among at least eight class 5 
 adhesins36, which is consistent with our observation that these nanobodies are broadly cross protective against 
multiple ETEC strains (Fig. 7G).
Discussion
ETEC strains are highly antigenically diverse, expressing over 25 types of adhesion factors. It has been very 
challenging to generate a pan-ETEC vaccine with broad coverage against diverse strains that cause diarrheal 
disease. In the present study, we used a llama immunization and a synthetic yeast library screen to identify and 
characterize a panel of nanobodies that recognize highly conserved epitopes on hypervariable adhesins. Among 
the 50 isolated nanobodies, four lead nanobodies showed broad coverage against 11 pathogenic ETEC strains 
and protected animals from infection.
Multimerization and IgA Fc fusion of nanobodies has emerged as an effective way to increase potency and 
mucosal half-life28. Recent studies have shown the feasibility of producing various formats of nanobodies in 
plants and microorganisms. High levels of VHH-IgA fusionbodies were effectively produced in yeast and soybean 
and have been proven efficient for mucosal protection against ETEC in  piglets33,37. Moreover, an anti-rotavirus 
VHH (ARP1) produced in yeast and rice could protect mouse pups against rotavirus-induced  diarrhea38,39. Oral 
administration of ARP1 produced in yeast was safe and effective in reducing diarrhea in male infants with severe 
rotavirus-associated  diarrhea40.
In the absence of a pan-ETEC vaccine, our study provides the first proof of concept that oral administration of 
a nanobody, prior to or during infection, could confer broad protection against various ETEC strains. The panel of 
nanobodies described in this study showed broad cross-protection against 11 major disease causing ETEC strains 
in HAI assay and prevented colonization in vivo when challenged by five out of six different ETEC strains tested.
Additionally, in order to further expand breadth of ETEC strain coverage by nanobodies, a cocktail of two 
or more nanobodies could be used.
Compared to Travelan, a commercial HBC product used to prevent ETEC-induced diarrhea, 1D7 VHH-IgA1 
fusionbody appears to be active in the mouse colonization model (1.7 log reduction in CFU) when adminis-
tered two hours prior to ETEC challenge and is effective at a lower dose (10 mg/kg of fusionbody vs 40 mg/kg 
of Travelan).
Amenability of nanobodies to modifications and optimizations, and technological advances in large-scale 
manufacturing of biological proteins in plants and microorganisms will make nanobody-based immunotherapy 
a potent and cost-effective prophylaxis or treatment for ETEC.
We previously described a positively charged binding pocket at the N-terminal domain of CfaE important 
for ETEC interaction with the negatively charged sialic acid on the host epithelial  cells8. This binding pocket is 
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formed by three arginine residues, R67, R181, and R182, and a cluster of surrounding residues, which are all 
highly conserved among the class 5 fimbrial adhesins. Mutations of the arginine residues result in a complete loss 
of binding activity of ETEC to host  cells34. The cross-protective nanobodies identified in this study were found 
to be focused on this critical site, providing a target for rational vaccine design to focus the immune response to 
this region. Recent work has highlighted the success of structure-based antigen design to elicit responses to key 
conserved epitopes, including for complex epitope  structures41. Experimental structural determination of one 
or more of these nanobodies bound to a representative fimbrial adhesin can confirm mapping-based binding 
models and serve as the basis for rational ETEC vaccine design to generate immunogens to elicit robust responses 
targeting this conserved site.
Figure 7.  Epitope mapping of lead anti-ETEC VHHs. (A–D) Figures showing molecular structures were 
generated with PyMOL version 1.8 (Schrodinger, LLC, New York, NY, 2016, PyMOL | pymol.org). BioLuminate 
software [BioLuminate, Schrödinger Release 2016‐4, Schrödinger, LLC, New York, NY,  BioLuminate® | 
Schrödinger (schrodinger.com)] was used to perform initial modeling of nanobodies and docking simulations 
to CfaE. Binding effects of alanine substitutions are shown on the CfaE structure (PDB code 2HB0) for lead 
VHHs (A) 2R215 and (D) 1D7, with close-up of putative receptor binding region (boxed in A,D) shown in 
(B) and (E). CfaE is shown as gray surface and cartoon, with residues tested by alanine scanning shown as 
spheres and colored by measured binding effects of CfaE alanine substitutions: major (+++, red), moderate 
(++, orange), minor (+, yellow), none (−, blue). Values correspond to those in Supplemental Table 2. To provide 
comparison of shared or distinct binding determinants, only residues with alanine scanning binding data for all 
nanobodies are shown. Residues are labeled in (A), (B), (D), (E), and residues that are fully conserved across 8 
fimbrial adhesins are boxed. Docking models of (C) 2R215 and (F) 1D7 VHHs bound to CfaE were generated 
using  ABodyBuilder44 and  ZDOCK35, with modeled bound VHHs shown as cyan cartoons. (G) Sequences of 
eight class 5 fimbrial adhesins were aligned using ClustalX algorithm. Inserts show regions in adhesion proteins 
where highly conserved residues (black box) required for nanobody binding are located.
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Methods
Antigen cloning, expression, and purification. The nucleic acid sequences of N-terminal adhesin 
domains of CfaE and class 5 adhesins (GenBank M55661) were cloned into a pMAL-C5X vector (Addgene) in-
frame with an MBP tag to express as periplasmic proteins with improved solubility (MBP–CfaE-N). The donor 
strand complement was included to ensure the overall protein expression and stability, as reported  previously42. 
All cloned constructs were transformed into SHuffleT7 Competent Escherichia coli (NEB), and expression was 
induced with 1 mM IPTG (isopropyl-d-thiogalactopyranoside). Bacteria were lysed, and proteins were purified 
with amylose resin (NEB) and eluted with 20 and 50 mM maltose (Sigma).
Llama immunization. Immunizations of llamas and library constructions were performed as described 
 previously28. Briefly, two male llamas were immunized with antigen cocktails that included eight class 5 coloni-
zation factors (300 μg each antigen, 2400 μg total for each animal). The first cocktail consisted of CS2, CS4, CS14, 
CfaE and the second cocktail consisted of CS19, CS17, CS1, and PCF071. The two antigen cocktails were injected 
into each animal weekly for six weeks and 150 ml blood was collected for isolation of RNA from the periph-
eral blood lymphocytes after the last immunization on the 7th week. Good immune response was observed 
in both animals against all antigens. RNA isolation and library constructions were performed by amplifying 
nanobody genes and ligating into a phagemid vector. Two phage display libraries were generated with a size 
of approximately 5 × 108 transformed E. coli TG1 bacteria and a correct insert ration of ~ 100%. Selection of 
target-binding nanobodies was performed by phage-display selections against immobilized antigen proteins on 
Maxisorp plates (NUNC, Thermo Fisher Scientific). The initial screening was performed against CS1 and CS2, 
followed by a second round of screening against the CfaE antigen. Phages were eluted by unspecific and competi-
tive elutions. Eluted phage were used to infect exponentially growing E. coli TG1 that were plated on Luria broth 
(LB) agar plates containing 2% (w/v) glucose and 100 µg/ml ampicillin. In addition, eluted phages were serially 
diluted, infected in TG1 and 5 µl spots of these infections were plated to allow estimating how many phages were 
eluted. Periplasmic extracts were prepared according to standard protocols involving overnight production in 
2YT medium and induction with IPTG. Extracts were tested for binding to all 8 Cfa antigens in ELISA. Based 
on HinfI digestion pattern, amino acid sequences and cross-reactive binding to Cfa antigens, unique candidate 
genes were selected for further characterization.
Yeast library screening. Yeast library screening was performed as previously  described29. For the first 
round of magnetic-activated cell sorting (MACS), 1 × 1010 of S. cerevisiae expressing a surface displayed library 
of synthetic  nanobodies29 were centrifuged, resuspended in binding buffer (20 mM HEPES pH 7.5, 150 mM 
NaCl, 2.8 mM  CaCl2, 0.05% MNG, 0.005% CHS, 0.1% BSA, 0.2% maltose) and then incubated with anti-fluo-
rescein isothiocyanate (FITC) microbeads (Miltenyi) and FITC labeled MBP for 40 min at 4 °C. Yeast cells were 
passed through an LD column (Miltenyi) to remove any yeast expressing nanobodies which interacted with the 
microbeads or MBP. The remaining yeast cells that flowed through the column were centrifuged, resuspended 
in binding buffer, and incubated with 1 µM of FITC-labeled N-terminal CfaE protein for 1 h at 4 °C. Yeast cells 
were then centrifuged, resuspended in binding buffer with anti-FITC microbeads, and incubated for 15 min 
at 4 °C before passing them into a LS column (Miltenyi) and collecting the eluate enriched for CfaE-binding 
nanobodies. The eluted yeast cells were expanded and used in a subsequent round of MACS to further enrich 
for CfaE-binding nanobodies. The second round was performed similarly to the first but beginning with 4 × 108 
yeast and substituting FITC-labeled CfaE with AlexaFluor647-labeled CfaE, and anti-FITC microbeads with 
anti-AlexaFluor647 microbeads. High affinity binding yeast cells were isolated with FACS. In the first round of 
FACS, yeast binding to 300 nM of AlexaFluor488 labeled CfaE were collected. These yeast clones were grown and 
subjected to second round of FACS in the presence of human monoclonal  antibody8 that was shown to bind in 
the proximity of the receptor binding domain. Clones that were outcompeted from binding to the antigen were 
collected. About 400 individual clones from two rounds of FACS were then grown, stained in a 96-well plate, 
assessed via flow cytometry for binding specificity to CfaE, and sequenced. 30 clones with unique sequences 
were isolated and chosen for further characterization, that included further panning with FITC-labeled class 5 
adhesins CS1 (class5b) and CS2 (class5c).
Nanobody purification. Nanobody sequences were cloned into pET-26b vector (EMD Millipore, Cat 
#69862) to express as a fusion protein with a C-terminal 6xHis tag. Sequence-verified clones were transformed 
into T7 Express lysY BL21 E. coli. Bacteria were grown in Terrific Broth containing 1 mM  MgCl2 and 0.01% 
glucose to an  OD600 = 0.7 before induction with 1 mM IPTG. Cells were harvested after overnight incubation at 
27 °C. Following the osmotic shock, nanobodies were purified from the periplasmic fraction by Ni-NTA chro-
matography (Gold Biotechnology) and dialyzed against PBS to remove imidazole.
ETEC strains. H10407 expressing CFA/I fimbriae was purchased from ATCC (ATCC 35401). ETEC strain 
H10407 was cultured on 2% agar containing 1% Casamino Acids (Sigma) and 0.15% yeast extract (Fisher Biore-
agents) plus 0.005%  MgSO4 (Sigma) and 0.0005%  MnCl2 (Sigma) (CFA agar plates) overnight at 37 °C. A total 
of 1 × 108 CFU/ml were resuspended in 20% glycerol (Sigma) in phosphate-buffered saline (PBS) solution and 
kept frozen at − 80 °C until needed. Strains expressing other adhesin molecules were obtain from University of 
Maryland. These strains included: #200145 (CS1), #201546 (CS2), #503046 (CS4), #400599 (CS14), #700056 
(CS17), #204648 (CS19), #100483 (CS3), #204348 (CS5), #100001 (CS6) and #100171 (CS21).
The growth conditions are the same as H10407.
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Generation of multimerization and VHH‑IgA fusion. Nanobodies were multimerized to dimeric or 
trimeric forms with (G4S) linkers. The dimeric forms were generated using 6 × (G4S) linker to connect two 
monomeric VHHs in tandem N terminus to C terminus orientation. Trimers were generated using two 3 × 
(G4S) linkers between monomeric nanobody units. The multimers were cloned into pET-26b vector adding 
a C-terminal 6xHis tag. Nanobodies were purified from the periplasmic fraction by Ni-NTA chromatography 
(Gold Biotechnology) and dialyzed against PBS to remove imidazole.
To generate VHH-IgA fusionbodies, monomeric nanobody sequences were cloned into a pcDNA 3.1 vec-
tor containing heavy chain constant region of IgA1 or IgA2 chains without the CH1 domain. Each vector was 
transformed in NEB5 competent cells, and sequences were verified ahead of transient transfection.
ELISA. 96-well plates (Nunc) were coated overnight at 4 °C with 2 µg/ml of purified MBP–CfaE-N. The plates 
were blocked with 1% BSA plus 0.05% Tween 20 in PBS for 1 h. Purified nanobodies were diluted in 1 PBS at a 
starting concentration of 20 μg/ml for 2R215, 2R23 and 1H4 and 0.2 μg/ml for 1D7, followed by 1:4 serial dilu-
tions in PBS, and added to the plates for 1 h. The plates were stained with hydroxy peroxidase-conjugated rabbit 
anti-camelid IgG Fc (1:10,000) for 1 h and developed using TMB Peroxidase substrate (SeraCare). Absorbance 
at an optical density at 450 nm  (OD450) was measured on an Emax precision plate reader (Molecular Devices).
Flow cytometry. Binding of the yeast surface expressing nanobodies to fluorescently labeled antigens was 
determined as described  previously29. Briefly, single clone pools were induced by galactose in Trp- media. 2 × 106 
cells were stained in selection  buffer29 in the presence of anti-AlexaFluor647 labeled HA antibody to monitor 
clone expression, and FITC labeled antigens with the final concentration of 100  nM. To determine whether 
nanobody was competing with functional antibody, antibody 68-61 at a concentration of 100-fold of reported 
Kd was included in the staining mixture. Yeast cells were washed, resuspended in the selection buffer and sub-
jected to flow cytometry on MACSquant.
Mannose‑resistant hemagglutination assay of human group A erythrocytes. H10407 strain 
cultures were taken from frozen cell banks and diluted in a sterile 0.15 M saline solution until an  OD600 of 1 was 
reached for the assay. H10407 cell bank was used at 1:4 dilution.
Other ETEC strains except #400599 (CS14) were cultured in ETEC medium containing 1% Casamino Acids 
(Sigma) and 0.15% yeast extract (Fisher Bioreagents) plus 0.005%  MgSO4 (Sigma) and 0.0005%  MnCl2 (Sigma) 
and 0.5 mg/ml of Deferoxamine (Sigma Aldrich). CS14-expressing strain (#400599) was cultured on 2% agar 
containing 1% Casamino Acids (Sigma) and 0.15% yeast extract (Fisher Bioreagents) plus 0.005%  MgSO4 (Sigma) 
and 0.0005%  MnCl2 (Sigma) (CFA agar plates) overnight at 37 °C plates. Bacteria were resuspended in 1 × PBS 
and dilutions were used to determine the concentration needed to inhibit hemagglutination.
Type A-positive human erythrocytes stored in K3EDTA were washed three times with 0.15 M saline solution 
and resuspended in the same solution to a final concentration of 1.5% (vol/vol). In a U-bottom 96-well plate 
(Nunc Thermo Scientific), 100 µl of nanobody was added in duplicate to the top row and diluted 1:2 down the 
plate in a 0.15 M saline solution. Fifty microliters of appropriately diluted ETEC was added to each well together 
with 50 µl of a 0.1 M d-mannose solution (Sigma). The plate was incubated for 10 min at room temperature. 
After incubation, 50 µl of blood solution was added to the plate and mixed well (200 µl final volume). Plates were 
allowed to sit stagnant at 4 °C for 2 h. Hemagglutination was then observed without the aid of magnification. The 
absence of a pellet of erythrocytes at the bottom of the well is indicative of positive hemagglutination. Blood was 
ordered fresh every other week from BioIVT- non-blood bank provider of human and animal biological matrices.
Caco‑2 adhesion assay. Caco-2 cells seeded at 1 × 104 cells/ml were grown in 96-well tissue culture plates 
containing Dulbecco’s modified Eagle’s medium (DMEM), at 37 °C in 5%  CO2 statically. H10407 strain of ETEC 
was grown overnight at 37 °C in ETEC medium containing 1% Casamino Acids (Sigma) and 0.15% yeast extract 
(Fisher Bioreagents) plus 0.005%  MgSO4 (Sigma) and 0.0005%  MnCl2 (Sigma). The next day, bacteria were 
resuspended in PBS and diluted until an  OD600 nm of 0.4 was reached. Antibody dilutions were set up in a deep 
well plate. Antibody dilutions and bacteria were combined at a 1:10 ratio and allowed to shake at 300 rpm for 1 h 
at room temperature. Meanwhile, Caco-2 cells were washed and incubated in antibiotic free DMEM containing 
500 µg/ml of a nanobody. After incubation, 0.035 ml of the mixture of antibody and bacteria was added to each 
well containing Caco-2 cells. The cells were then incubated statically for 3 h at 37 °C. The cells were then washed 
four times with 1 ml PBS to remove non adherent ETEC cells and intensity of luciferase signal was determined.
Mouse intestine colonization assays. All methods used in animal work were carried out in accordance 
with relevant guidelines and regulations.
All experimental protocols were approved by UMASS Medical School Institutional Animal Care and Use 
Committee (IACUC) and Institutional Bio-Safety Committee (IBC).
Six- to eight-week-old DBA/2 mice were pretreated with streptomycin (5 g/l) in the drinking water for 
24–48 h. Twelve hours prior to bacterial administration, the water bottle was replaced with regular drinking 
water. One hour prior to bacterial administration, mice received cimetidine (50 mg/kg) intraperitoneally to 
reduce the effect of stomach acid on ETEC. A total of 1 × 107 CFU of ETEC strains diluted in PBS were incubated 
with 100 mg/kg of monomeric anti-CfaE nanobody or an irrelevant nanobody 1 h prior to challenge. In pre-mix 
model, bacteria and nanobody were mixed and administered in 200 µl volume by oral gavage using 20-gauge 
bulb-tip feeding needles. In the pre-treatment model, mice were pre-treated with nanobody in 200 µl volume in 
PBS via oral gavage. One or two hours later, bacteria were administered in 100 µl PBS by oral gavage. The mice 
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were allowed to survive for 24 h. At 12 h before euthanasia, food was withdrawn. Following isolation of the small 
intestine, two segments of the ileum (3 cm each), beginning within 0.5 cm of the ileocecal junction and extend-
ing proximally 6 cm, were removed and placed in 1 ml sterile  PBS43. Tissues were mechanically homogenized. 
Samples were serially diluted on MacConkey agar plates and incubated overnight at 37 °C. Bacterial CFU were 
counted the next day.
Epitope mapping. Alanine mutants of CfaE residues were cloned individually by Genscript into pMAL-
C5x vector, and the resulting constructs were transformed, expressed, and purified as described above. ELISA 
was performed to determine the binding of the nanobodies to the mutant proteins in comparison to that of the 
wild type.
Molecular modeling. BioLuminate software (BioLuminate, Schrödinger Release 2018-3, Schrödinger, 
LLC, New York, NY) was used to perform initial modeling of nanobodies and docking simulations to CfaE. Sub-
sequent modeling of nanobody structures was performed using the ABodyBuilder antibody modeling  server44 
(with default parameters) followed by docking simulations using the ZDOCK  server35 with default ZDOCK pro-
tocol (version 3.0.2), and the structure of unbound CfaE (PDB code 2HB0). To avoid docking models with nano-
bodies bound to the CfaE C-terminal domain, CfaE residues 200 and above were blocked on the server. ZDOCK 
server models were post-processed using the Fraction of Common Contacts (FCC) clustering  algorithm45 to 
identify prevalent predicted nanobody-CfaE recognition modes among all 2000 ZDOCK models for each com-
plex, using a contact identity cutoff of 0.75 as suggested by FCC documentation. Manual inspection of exemplars 
from most populous clusters for each interaction, to compare CfaE interface residues of models with epitope 
mapping data, was used to select docking model candidates. Figures showing molecular structures were gener-
ated with PyMOL version 1.8 (Schrodinger, LLC, New York, NY).
Statistical analysis. Statistical calculations were performed using the software Prism version 7.03 (Graph-
Pad Software, La Jolla, CA). Comparisons in colonization experiments were performed using one-way analysis 
of variance (ANOVA) with Bonferroni correction for post hoc multiple comparisons.
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